Business Description
Oncoclinicas Do Brasil Servicos Medicos SA
ISIN : BRONCOACNOR6
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.53 | |||||
Debt-to-EBITDA | 5.5 | |||||
Interest Coverage | 1.23 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.11 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.5 | |||||
3-Year EBITDA Growth Rate | 78.3 | |||||
3-Year FCF Growth Rate | -141.7 | |||||
3-Year Book Growth Rate | 65.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 28.59 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.96 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 1.33 | |||||
9-Day RSI | 4.22 | |||||
14-Day RSI | 8.96 | |||||
6-1 Month Momentum % | -49.78 | |||||
12-1 Month Momentum % | -55.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.96 | |||||
Quick Ratio | 1.87 | |||||
Cash Ratio | 0.85 | |||||
Days Inventory | 19.81 | |||||
Days Sales Outstanding | 81.79 | |||||
Days Payable | 79.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.2 | |||||
Shareholder Yield % | -129.81 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 33.54 | |||||
Operating Margin % | 12.05 | |||||
Net Margin % | 1.19 | |||||
FCF Margin % | -10.87 | |||||
ROE % | 2.51 | |||||
ROA % | 0.7 | |||||
ROIC % | 6.72 | |||||
ROC (Joel Greenblatt) % | 43.59 | |||||
ROCE % | 9.54 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 17.26 | |||||
Forward PE Ratio | 5.62 | |||||
PE Ratio without NRI | 12.92 | |||||
PEG Ratio | 0.26 | |||||
PS Ratio | 0.2 | |||||
PB Ratio | 0.38 | |||||
EV-to-EBIT | 6.42 | |||||
EV-to-Forward-EBIT | 4.25 | |||||
EV-to-EBITDA | 4.75 | |||||
EV-to-Forward-EBITDA | 3.36 | |||||
EV-to-Revenue | 0.82 | |||||
EV-to-Forward-Revenue | 0.68 | |||||
EV-to-FCF | -9 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.22 | |||||
Earnings Yield (Greenblatt) % | 15.59 | |||||
FCF Yield % | -48.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Oncoclinicas Do Brasil Servicos Medicos SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 6,095.433 | ||
EPS (TTM) (R$) | 0.128 | ||
Beta | 1.77 | ||
Volatility % | 62.85 | ||
14-Day RSI | 8.96 | ||
14-Day ATR (R$) | 0.307754 | ||
20-Day SMA (R$) | 3.9025 | ||
12-1 Month Momentum % | -55.36 | ||
52-Week Range (R$) | 2.15 - 13 | ||
Shares Outstanding (Mil) | 632.79 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oncoclinicas Do Brasil Servicos Medicos SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oncoclinicas Do Brasil Servicos Medicos SA Stock Events
Event | Date | Price(R$) | ||
---|---|---|---|---|
No Event Data |
Oncoclinicas Do Brasil Servicos Medicos SA Frequently Asked Questions
What is Oncoclinicas Do Brasil Servicos Medicos SA(BSP:ONCO3)'s stock price today?
When is next earnings date of Oncoclinicas Do Brasil Servicos Medicos SA(BSP:ONCO3)?
Does Oncoclinicas Do Brasil Servicos Medicos SA(BSP:ONCO3) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |